Biopharmaceutical News and Research

RSS

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

Biotech Showcase inks pact with Astia to help women-led biotech companies

EBD Group and Demy-Colton Life Science Advisors, the producers of Biotech Showcase™, and Astia today announced a strategic collaboration designed to ensure that women-led biotech companies gain the investor and industry relationships needed to successfully grow their businesses.

12 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Santarus, Inc., a specialty biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, today announced that they have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialize prescription immediate-release ZEGERID® products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe.

12 Oct 2009

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its anti-inflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.

12 Oct 2009

Pieris reports its progress in the development of PRS-050

Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.

12 Oct 2009

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

Government of Quebec develops new strategy to strengthen biopharmaceutical sectors

In the midst of challenging economic times, the announcement of the Quebec government's biopharmaceutical strategy is good news for basic pharmaceutical research and patient access to innovative medicines, said Dawn Graham, President of Merck Frosst Canada today in response to the release of the Quebec Pharmaceutical Strategy.

9 Oct 2009

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.

9 Oct 2009

The Quebec Biopharmaceutical Strategy lauded by Sanofi-aventis

Sanofi-aventis Canada welcomes the Quebec Biopharmaceutical Strategy and sees a strong link with its new corporate strategy.

9 Oct 2009

New series of business intelligence tools from Deloitte Recap

Deloitte Recap LLC (Recap) has launched the first two products in the Recap IQ Series by Deloitte, a new subscription service that provides analytical tools built on rich databases tailored toward business development, corporate strategy, financial, legal, tax and R&D professionals.

9 Oct 2009

Halozyme Therapeutics to host a meeting for analysts and investors

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 15 in New York.

8 Oct 2009

Epizyme raises $32 million through its Series B financing

Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC).

8 Oct 2009

Aryx Therapeutics to raise up to $35 million from sale of its common stock

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has secured a committed equity financing facility under which it may sell up to $35 million of shares of its common stock to Commerce Court Small Cap Value Fund, Ltd. (“Commerce Court”) over a 24 month period. The maximum number of shares that can be sold by ARYx is specified in the agreement. ARYx is not obligated to utilize any of the $35 million facility and remains free to enter into and consummate other equity and debt financing transactions.

7 Oct 2009

Shire publishes efficacy study results of FOSRENOL and Renagel

Shire plc, the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

7 Oct 2009

aTyr Pharma to discuss aminoacyl tRNA synthetases at the BioPartnering Europe Conference

aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring proteins as biotherapeutics, will present at the BioPartnering Europe Conference in London on Monday October 12. Jeff Watkins, CEO of aTyr Pharma, will provide an overview of aTyr Pharma's technology, product engine, and lead program based on naturally occurring resected proteins of the tRNA synthetases.

7 Oct 2009

Werum Software & Systems opens new subsidiary in France

On October 1st, German software provider Werum Software & Systems AG officially opened its new subsidiary Werum Software & Systems SAS in France.

7 Oct 2009

EnWave files a patent application for nutraREV equipment in Canada

EnWave Corporation has received positive comments from the Patent Examiner with regard to the Company's Patent Co-Operation Treaty ("PCT") patent application for nutraREVTM equipment concept and use, leading the Company to believe that a favorable International Preliminary Report on Patentability ("IPRP") is forthcoming.

7 Oct 2009

NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD

The winner of the 2009 EUROPEAN BIOTECHNICA AWARD is NovImmune SA from Switzerland. This biopharmaceutical company duly receives the lion’s share of the €100,000 prize money, which is awarded each year by Deutsche Messe AG and its partners. The aim of the award is to celebrate the achievements of innovative European companies in the field of biotechnology and the life sciences.

6 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

Biopharmaceutical News and Research

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Biotech Showcase inks pact with Astia to help women-led biotech companies

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Santarus and Norgine enter into a licensing agreement for ZEGERID products

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

Pieris reports its progress in the development of PRS-050

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Government of Quebec develops new strategy to strengthen biopharmaceutical sectors

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

The Quebec Biopharmaceutical Strategy lauded by Sanofi-aventis

New series of business intelligence tools from Deloitte Recap

Halozyme Therapeutics to host a meeting for analysts and investors

Epizyme raises $32 million through its Series B financing

Aryx Therapeutics to raise up to $35 million from sale of its common stock

Shire publishes efficacy study results of FOSRENOL and Renagel

aTyr Pharma to discuss aminoacyl tRNA synthetases at the BioPartnering Europe Conference

Werum Software & Systems opens new subsidiary in France

EnWave files a patent application for nutraREV equipment in Canada

NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

How to optimize your cell line development eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News